Ticho Barry 4

What Happened

• Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), reported multiple open‑market sales and an option/derivative exercise between March 17–19, 2026. He sold a total of 14,311 shares in several transactions (aggregate proceeds ≈ $456,835). On March 19 he also exercised/converted 1,365 derivative shares at $2.19 per share (total paid ≈ $2,989).
• These were predominantly sales (routine/liquidity), with a small option exercise (acquisition). Some sales were related to tax withholding on vested awards and at least one transaction was executed under a Rule 10b5‑1 plan.

Key Details

• Transaction dates and amounts:
  • 2026-03-17: Sold 3,577 shares @ $32.74 = $117,109 (weighted avg pricing noted)
  • 2026-03-17: Sold 2,587 shares @ $33.38 = $86,342 (weighted avg)
  • 2026-03-18: Sold 6,100 shares @ $31.28 = $190,831 (weighted avg)
  • 2026-03-18: Sold 483 shares @ $31.79 = $15,354
  • 2026-03-18: Sold 103 shares @ $32.85 = $3,384
  • 2026-03-19: Exercised/converted 1,365 shares @ $2.19 (Acquired) = $2,989
  • 2026-03-19: Sold 1,461 shares @ $29.99 = $43,815
  • 2026-03-19: A derivative disposition of 1,365 shares recorded at $0 (reported as a derivative transaction)
• Aggregate: 14,311 shares sold for ≈ $456,835; 1,365 shares acquired via exercise for ≈ $2,989.
• Shares owned after the transactions: not specified in the filing.
• Notable footnotes from the filing:
  • F1: Some sales were issuer‑mandated to satisfy tax withholding on vesting/settlement of restricted stock units.
  • F2–F5: Reported prices are weighted averages; the filing gives specific price ranges for multiple trade blocks.
  • F6: At least one sale was executed under a Rule 10b5‑1 trading plan adopted Nov 19, 2025.
  • F7: The option exercised is fully vested and exercisable.
• Filing timeliness: Form 4 was filed on March 19, 2026 for transactions dated Mar 17–19, 2026 — within the normal 2‑business‑day filing window (not flagged as late).

Context

• Sales by executives are common for liquidity or tax purposes; here the filing explicitly notes issuer‑mandated sales to cover taxes and a 10b5‑1 plan for at least one transaction. Those circumstances typically indicate routine reasons rather than a direct statement about the executive’s view of the company.
• For the derivative activity: the filing shows an exercise/conversion (1,365 shares acquired at $2.19) plus a related derivative disposition recorded at $0; footnotes indicate the option was fully vested. This pattern can reflect exercise/settlement mechanics (including any net or cashless settlement or conversion), but the filing provides the facts without stating a motive.